Related Experiment Videos
Is MCTD a distinct entity? Comparison of clinical and laboratory findings in MCTD, SLE, PSS, and RA patients
L S De Clerck1, K A Meijers, A Cats
1Department of Rheumatology, Leiden University Hospital, The Netherlands.
Abstract:
Eighteen patients diagnosed as suffering from MCTD were reexamined during follow-up (mean duration 4.6 years). The clinical features of these patients were compared with those of 19 patients with systemic lupus erythematosus (SLE), 11 with progressive systemic sclerosis (PSS) and 22 with rheumatoid arthritis (RA). Considerable overlapping of abnormal features was found between MCTD and the other syndromes. At the end of the follow-up period, 70 per cent of the cases initially diagnosed as MCTD evolved to a more classical connective tissue disease, i.e., either PSS or SLE. Generally, however, the clinical evolution of the individual MCTD patient was not predictable. Abnormal aortic valve calcifications were found in the MCTD group. Four of the 18 MCTD patients were anti-RNP negative at reexamination. There was a tendency for HLA antigens B7 and B8 to be increased in the MCTD group, but this difference was not statistically significant. Three MCTD patients died before they could be reexamined (two of them from pulmonary hypertension with proliferative endarteritis of the lung vessels and one from septicaemia and multiple cerebral infarctions.
Insights
Many patients initially diagnosed with mixed connective tissue disease (MCTD) evolve into more specific conditions like systemic lupus erythematosus or progressive systemic sclerosis over time. Clinical outcomes for MCTD patients are generally unpredictable.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Mixed connective tissue disease (MCTD) presents with overlapping features of other autoimmune rheumatic diseases.
- Longitudinal studies are crucial for understanding the natural history and evolution of MCTD.
Purpose of the Study:
- To reexamine patients diagnosed with MCTD and compare their clinical features over time.
- To determine the evolution of MCTD into more defined connective tissue diseases (CTDs).
- To identify potential predictors of clinical course and outcomes in MCTD.
Main Methods:
- Follow-up reexamination of 18 patients initially diagnosed with MCTD.
- Comparative analysis of clinical features with patients diagnosed with systemic lupus erythematosus (SLE), progressive systemic sclerosis (PSS), and rheumatoid arthritis (RA).
- Assessment of clinical evolution, serological markers (anti-RNP), and HLA antigen associations.
Main Results:
- Significant overlap in clinical features was observed between MCTD and SLE, PSS, and RA.
- 70% of initially diagnosed MCTD patients evolved into either PSS or SLE.
- Abnormal aortic valve calcifications were noted in the MCTD group; clinical evolution was largely unpredictable.
- Three MCTD patients died due to pulmonary hypertension, septicaemia, and cerebral infarctions.
Conclusions:
- MCTD often represents an evolving or undifferentiated CTD that may manifest as a more classical CTD (SLE or PSS) over time.
- The clinical course of individual MCTD patients is unpredictable.
- Further research is needed to elucidate the pathogenesis and identify prognostic markers for MCTD.